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SHORT-COURSE 
IMMUNOSUPPRESSION 
AFTER TRACHEAL 
ALLOTRANSPLANTATION IN 
DOGS 
It is desirable to minimize immunosuppression after allotransplantation. We 
examined the usefulness of a short course of immunosuppression after tracheal 
allotransplantation i  35 dogs. Five animals with six-ring tracheal autografts erved 
as controls (group I, n = 5). Thirty animals with six-ring tracheal allografts were 
randomly classified into five groups as follows: no immunosuppression (group II, 
n = 6), azathioprine for only 1 postoperative week (group III, n = 7), azathioprine 
for 2 postoperative weeks (group IV, n = 7), azathioprine for 3 postoperative weeks 
(group V, n = 5), and mizoribine for 3 postoperative weeks (group VI, n = 5). All 
allografts in groups II through VI sustained rejection, but there was no ditference in 
mononuclear cell infiltration of the grafts among the groups. The only grafts with 
long-term viability were those in groups I and VI, as demonstrated by graft patency 
and epithelialization. We conclude that immunosuppression with mizoribine for 
only a short course after transplantation may allow long-term viability of tracheal 
allografts. (J THORAC CARDIOVASC SURG 1995;109:910-7) 
Ryoichi Nakanishi, MD, Kosei Yasumoto, MD, Kitakyushu, Japan, 
and Takayuki Shirakusa, MD, Fukuoka, Japan 
I mmunosuppressive agents are necessary to pre- 
vent rejection of transplanted organs. However, 
long-term administration of these agents is associ- 
ated with significant complications including the 
development of malignant disease. 1 Therefore, min- 
imizing immunosuppression after transplantation is 
desirable. 
Tracheal allotransplantation generally requires 
immunosuppression. 2 However, it has been re- 
ported that tracheal allotransplants, in contrast o 
other organ transplants, induce only weak graft 
rejection even in the presence of major histoincom- 
patibility. 3 If this is the case, minimal immunosup- 
pression may prevent rejection. To date, no report 
on the required strength of immunosuppression f r
tracheal allografts has been presented. 
This study was undertaken to assess the effective, 
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ness of a short course of immunosuppression after 
tracheal allotransplantation because irreversible 
early rejection reactions may occur after transplan- 
tation without immunosuppression. In cases with 
weak rejection reactions, a short course of postop- 
erative immunosuppression maintains long-term al- 
lograft viability, even if the late rejection occurs. A 
short course of immunosuppression is preferable to 
consecutive courses of immunosuppression n terms 
of side-effects. 
Materials and methods 
Animals. Thirty-five adult mongrel dogs weighing from 
8.5 to 16.5 kg were premedicated with an intramuscular 
injection of ketamine hydrochloride (20 mg/kg). Five 
individual dogs and 15 pairs of dogs were placed in the 
supine position and anesthetized with an intravenous 
injection of pentobarbital sodium (10 mg/kg) and pancu- 
ronium bromide (0.1 mg/kg). Then they were intubated 
orally and connected toa pressure-limiting respirator. All 
animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH Publica- 
tion No. 86-23, revised 1985). 
Surgical technique. After an upper midline laparot- 
omy, an omental pedicle, which was fed by the right 
gastroepiploic artery, was formed without a splenectomy. 4 
The trachea was then exposed after a midline cervical 
incision and was mobilized circumferentially. The fifth 
tracheal ring was the uppermost ring resected. A spiral 
endotracheal tube was positioned into the lower trachea 
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after the resection of six tracheal rings. The resected 
trachea was used as an autograft in group I and switched 
between paired animals as an allograft iß groups II to VI. 
The upper anastomosis was first completed with running 
3-0 Dexon sutures (Davis & Geck, Inc., Manati, Puerto 
Rico). Next, the membranous portion of the lower anas- 
tomosis was similarly sutured. The spiral endotracheal 
tube was then removed from the operative field and the 
oral endotracheal tube was passed through both the upper 
and lower suture lines. The lower anastomosis was subse- 
quently completed. An omental pedicle was brought up 
via a diaphragmatic defect through the mediastinum to 
the cervical area. This pedicle was used to wrap each end 
of the grafl. The cervical and abdominal incisions were 
then closed in the usual fashion. 
Postoperative management.-The animals received an- 
tibiotics for the first 14 postoperative days. The 30 animals 
in groups II to VI were randomly classified into five 
groups according to immunosuppression (Table I): group 
II (n = 6), no immunosuppression; group III (n = 7), 
azathioprine (Azanin; Tanabe Pharmaceutical Co., Ltd.: 5 
mg/kg per day) for 1 postoperative week; group IV (n = 
7), azathioprine for 2 postoperative weeks; group V (n = 
5), azathioprine for 3 postoperative weeks; and group VI 
(n = 5); mizoribine (Bredinin; Asahikasei Co., Ltd.: 5 
mg/kg per day) for 3 postoperative weeks. All drugs were 
administered by mouth. Bronchoscopic examinations 
were performed weekly after the operation until these 
animals died of natural causes or were killed. 
Assessment of grafts 
Patency. The patency of the tracheal graft was assessed 
by calculating the percent patency after the animal had 
died. The graft percent pateney was expressed as a 
proportion of the cross-sectional rea (CSA) of the most 
stenotic site in the graft to the third tracheal ring below 
the cricoid cartilage in the recipient trachea. The CSA was 
calculated from the following formula: CSA = a/2 × b/2 × 
~r, where a was the transverse diameter and b was the 
sagittal diameter. »
Histologic assessment. All tissues were fixed in 10% 
formalin. Microscopic slides were made from longitudinal 
sections of the trachea and adherent omentum and 
stained routinely with hematoxylin-eosin. Thereafter, all 
specimens were examined with a light microscope. We 
attempted to quantify the viability of the orthotopic 
grafted trachea by subjectively evaluating the epithelial 
histologic haracteristics. Infiltration by mononuclear cells 
was also assessed because this is closely associated with 
allograft rejection. ó 
EPITHZUAL REGZNEgnTION. Epithelial regeneration was 
evaluated according to the following grading system: 0, no 
epithelium; 1, single-layer nonciliated epithelium; 2, mul- 
tflayer nonciliated epithelium; and 3, normal mucociliary 
epithelium. 2 The epithelium of the gratis was assessed as 
a ratio of the epithelial regeneration store on a micro- 
scopic slide. 
MONONUCLEAR CELL INFILTRATION. The severity of mono- 
nuelear cell infiltration was graded semiquantitatively 
from 0 to 3, with 0 indicating absence of any abnormality, 
1 mild (infiltration area < 30% of a microscopically visual 
field), 2 moderate (30% < infiltration area < 70%), and 3 
severe changes (infiltration area > 70%). 7 
Table I. Study groups 
Medication interval of 
immunosuppressive ag nt 
Group n Grafting Azathioprine Mizoribine 
I 5 Auto - -  - -  
II 6 Allo - -  - -  
III 7 /kilo 7 - -  
IV 7 Allo 14 - -  
V 5 Allo 21 --  
VI 5 Allo - -  21 
--, no medication. Azathioprine (Azanin, 5mg/kg per day) and mizoribine 
(Bredinin, 5mg/kg per day) were administered by mouth. 
Statistical methods. The probability of survival was 
calculated by the Kaplan-Meier method. 8 The significance 
of the differences in survival rate was computed by the 
log-rank test. 9 All data as to patency, epithelial regener- 
ation score, and mononuclear cell infiltration score of the 
gratis were presented as the mean and standard error. 
Statistical analysis was performed by rneans of the SAS 
software package (SAS Institute, Cary, N.C.). A p value 
less than 0.05 was considered statistically significant. 
Results 
Bronchoscopic findings. All the tracheal al- 
lografts, except for those in group II, showed grad- 
ual relief of severe inflammatory changes during 
immunosuppression. After immunosuppression was 
discontinued, the allografts appeared similar to 
those without immunosuppression (group II). They 
showed progressive stenosis caused by granulation 
tissue or exposure of the cartilaginous rings, or both. 
The allografts of long-term survivors in groups IV 
and V (dogs 20, 24, and 25) revealed that the 
stenosis was less severe. Autografts in group I and 
allografts in group VI dernonstrated good patency and 
intact mucosa after the first postoperative month. 
Survival (Table II). All animals in group I sur- 
vived more than 1 month and were then killed for 
the purpose of assessing raft viability. Although it 
was hoped that all anirnals in groups II to VI  would 
survive for a long period, almost all animals except 
for those in group VI  died within I year. All animals 
in group VI  were put to death 2 years after trans- 
plantation for the purpose of making apparent he 
difference between their survival and that of the 
animals in groups I I  to V. Thirteen (43.3%) animals 
in groups II to VI  died of airway stenosis f fom graft 
rejection. The mean survival time of each group was 
as follows: group II, 8 days; group III, 16 days; group 
IV, 30 days; group V, 36 days; and group VI, 797 
days. In groups II, I I I ,  and IV one animal survived 
longer than 1 month. In contrast, all animals in 
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Table I I .  Survival and allograft status 
Dog Survival 
Groups (No.) (days) Cause of death Grafi status 
No immunosuppression group 
Group II (n = 6) 
Immunosuppression groups 
Group III (n = 7) 
Group IV (n = 7) 
Group V(n = 5) 
Group VI (n = 5) 
1 4 General marasmus Ischemic 
2 6 Diaphragmatic hernia Partial dissolution 
3 8 Airway stenosis Total dissolution 
4 12 General marasmus Partial dissolution 
5 18 Airway stenosis Partial dissolution 
6 38 Airway stenosis Midportion stenosis; large granulation 
7 8 General marasmus 
8 9 Diaphragmatic hernia 
9 14 Airway stenosis 
10 16 Airway stenosis 
11 18 Airway stenosis 
12 22 Tracheoesophageal flstula 
13 33 Airway stenosis 
14 21 Airway stenosis 
15 25 Airway stenosis 
16 28 Pneumonia 
17 30 General marasmus 
18 30 Airway stenosis 
19 31 Airway stenosis 
20 343 Upper GI tract bleeding 
21 34 Airway stenosis 
22 34 Pneumonia 
23 36 Airway stenosis 
24 93 Diaphragmatic hernia 
25 280 Killed 
26 771 Killed 
27 781 Killed 
28 797 Källed 
29 798 Killed 
30 811 Killed 
Ischemic 
Ischemic 
Total dissolution 
Midportion stenosis; large granulation 
Total dissolution 
Partial dissolution 
Midportion stenosis; large granulation 
Midportion stenosis; large granulation 
Overall stenosis; large granulation 
Almost healed; normal mucosa 
Midportion stenosis; some granulation 
Total dissolution 
Malaeia of the midportion, some granulation 
Midportion stenosis; some granulation 
Overall stenosis; large granulation 
Slightly healed; loss of mucosa 
Midportion stenosis; large granulation 
Almost healed; normal mueosa 
Weil healed; normal mucosa 
Almost healed; normal mucosa 
Almost healed; normal mueosa 
Slight stenosis; normal mucosa 
Almost healed; normal mucosa 
Well healed; normal mucosa 
G/, Gastrointestinal. 
groups V and VI  survived more than 1 month. The 
cumulative survival was significantly longer in group 
VI  than in groups I I  to V. Likewise, the survival in 
group V was significantly longer than in group I I  or 
I I I .  There was no difference in survival among the 
groups (Fig. 1). 
Graft status and percent patency (Table II). All 
the autografts in group I had normal appearing 
mucosa and good patency, and almost all were 
healed. Stenosis and dissolution of the allograft in 
groups I I  to VI  were seen in 19 animals (63.3%). No 
animal in group VI  had significant stenosis (less 
than 60% of normal) or dissolution. In group V, 
stenosis of the graft was seen in two of five animals. 
Allografts in the remaining three animals showed 
healing status. In groups II, l I I ,  and IV, more than 
70% of animals had stenosis or dissolution (or both) 
of the allograft. Dissolution of the graft was seen in 
four of six animals in group II. The average graft 
patency was significantly better in group I than in 
groups II, I I I ,  IV, and V but did not differ f rom that 
of group VI (Fig. 2). The rates of stenosis or 
dissolution of the allograft decreased in proport ion 
to duration of immunosuppression. 
Histology 
Epithelial regeneration. All the animals in group I 
had good epithelial regenerat ion in the autografts. 
Two animals (33%) in group II, four (57%) in group 
II I ,  and five (71%) in group IV demonstrated some 
reepitheliälization of the allografts. These allografts 
had partial restoration of the epithelium, which was 
almost completely occupied with a single layer of 
noncil iated epithelium (Fig. 3). In groups V and VI, 
all allografts demonstrated epithelial regeneration. 
Single-layer and multi layer noncil iated epithelium 
was often seen in the allografts of group V. Al- 
lografts in group VI  often demonstrated normal 
mucocil iary epithelium (Fig. 4). The average pithe- 
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Cnoup III ; Azathiowine for I week (n=7) 
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Group V ; Azathioprine for 3 weeks (n=5) 
Group Vl ; Mizoribine for 3 weeks (n=5) 
Fig. 1. Cumulative percent survival after tracheal allotransplantation in groups II to VI. The survival of 
group VI differed significantly from the survival of other groups (groups VI versus I I ,p = 0.0065; VI versus 
III, p = 0.0057; VI versus IV, p = 0.007; and VI versus V, p = 0.0094). Survival in group V differed 
significantly from the survival of groups II (p = 0.0486) and III (p = 0.0057). In other comparisons of 
survival between groups, there was no difference. 
lial regenerat ion score of grafts in group I was 
significantly better than that of groups II, I I I ,  IV, 
and V but did not differ from that of group VI  (Fig. 5). 
Mononuclear cell infiltration. All allografts except 
for those in group VI  revealed a slight to moderate 
mononuclear  cell infiltration. Allografts in group VI  
demonstrated only slight infiltration by mononu-  
clear cells. However,  there was no significant differ- 
ence in the mononuclear  cell infiltration score 
among groups I I  to VI  (Fig. 6). 
The per ichondrium of the cartilaginous rings and 
the cartilage itself was destroyed by mononuclear  
cells in some of the allografts in all groups except for 
group VI. The cartilage of the allografts in group VI  
retained their structural integrity. Interstit ial  dam- 
age was moderate to severe in groups I I  to IV  but 
was only mild in group VI. The grafts in group V 
had intermediate interstitial damage between 
groups I I  to IV  and VI. Prol iferation of granulation 
tissue and hemorrhage was seen in almost all the 
allografts in groups I I  to IV  but was rarely seen in 
group VI. Necrosis of the allografts was seen in 
animals who survived less than 30 days in groups I I  
to V but was not seen at all in group VI. Moderate 
Patency (%) 
100 
80 
60 
40 
20 
GroupI GrouplI Grouplll Group IV GroupV GroupV1 
Control No Tx, lw 2w 3w 3w 
I I 
Azathioprine Mizoribine 
Fig. 2. Average graft patency. Data are presented as 
mean -+ standard error. No Tx. indicates no treatment. 
The average patency of group I differed significantly from 
the patency of other four groups (groups I versus II, p = 
0.0123; I versus III, p = 0.0316; I versus IV, p = 0.0149; 
and I versus V,p = 0.0381), but did not differ significantly 
from the patency of group VI (p = 0.4443). The average 
patency of group VI differed significantly from the patency 
of groups II, III, and IV. 
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Fig. 3. Histologic study of an allograft of canine trachea onthe postoperative day 343 in group IV (dog 
20). The epithelium is partially restored (32.5%) and iscomposed of a single layer of nonciliated epithelium 
alone (epithelial regeneration sc re= 0.325). The mononuclear cells infiltrate moderately into the 
subepithelial region of the allograft. (Hematoxylin and eosin; original magnification x400.) 
to severe infiammation occurred in all of the remain- 
ing allografts of groups II to IV. In contrast, allografts 
in group VI showed only slight inflammatory changes. 
Discussion 
With few exceptions, tracheal allotransplantation 
has been largely unsuccessful. Two major difficulties 
have been encountered. 1° One is the revasculariza- 
tion of the devascularized tracheal graft. The other 
difficulty is rejection. Problems with revasculariza- 
tion have been improved by the addition of omen- 
topexy, al The omental blood supply can maintain 
the viability of tracheal autografts less than 4 cm in 
length. 5 In the diagnosis of rejection, epithelial 
morphology isvaluable in identifying early rejection, 
because of its close association with epithelial regen- 
eration.6, 7 Thus the problem of immunosuppression 
must be studied in tracheal allotransplantation. 
Allograft rejection can be both acute and chronic. 
Immunosuppression is commonly effective against 
acute rejection, but its role in chronic rejection still 
remains unclear because the mechanism of chronic 
rejection is not defined. Currently, consecutive im- 
munosuppressive therapy for allografts, such as in- 
tensive immunosuppression i  the acute phase 
which is tapered in the chronic phase, often is used 
clinically. 12 The use of a short course of immuno- 
suppression after transplantation is uncommon. 
Therefore, it is difficult to determine the most 
effective and shortest period of immunosuppression 
appropriate for tracheal allografts. Recognizing the 
tracheal allograft as the sensitizing antigen may take 
a relatively long time because the allografts are not 
vascularized initially, and revascularization occurs 
later. As a result, rejection of the allograft begins 
later, in contrast o other organ transplants. In out 
previous studies, the histopathologic status of al- 
lograft rejection was clearly apparent by 10 days 
after transplantation. 7 Davreux and associates z have 
reported that early rejection was apparent histolog- 
ically by 14 days after transplantation. Therefore, 
tracheal allografts may require intensive immuno- 
suppression for at least 14 days. In these current 
experiments, dogs with allografts in groups II, III, 
and IV, which received azathioprine for less than 14 
days, showed no difference in such parameters as 
survival, graft patency, epithelial regeneration, and 
mononuclear cell infiltration. In contrast, three of 
five dogs with allografts in groups V, which received 
azathioprine for 21 days, demonstrated improved 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 5 
Nakanishi, Yasumoto, Shirakusa 9 1 5 
Fig. 4. Histologic study of an allograft of canine trachea on the postoperative day 811 in group VI (dog 
30). The epithelium is almost restored and is composed of nearly normal mucociliary epithelium (72.5%) 
(epithelial regeneration score = 2.45). The mononuclear cells infiltrate only slightly into the subepithelial 
region of the graft. (Hematoxylin and eosin; original magnification ×250.) 
gross healing. The patency and epithelial regenera- 
tion of allografts in group V were slightly better than 
those of groups II, III, and IV. Therefore, it is 
thought hat tracheal allografts may require immu- 
nosuppression for at least 21 days. 
We used azathioprine and mizoribine as immuno- 
suppressive agents in these experiments because 
these two agents can influence both cell-mediated 
and humoral immune reactions. 13 These agents po- 
tentially induce the allografts to attain immune 
tolerance because they suppress both T and B 
lymphocytes. 14 Azathioprine is a conventional im- 
munosuppressant and has been used with cortico- 
steroids in tracheal transplantation. 1° In contrast, 
mizoribine, an imidazole nucleoside isolated from 
Eupenicillium brefeldianum M-2166, is a compara- 
tively new drug and was originally developed as a T 
cell inhibitor. 14 It was then found that mizoribine 
suppresses antibody generation by directly acting on 
B cells as well as by indirect action through the 
modulation of T cells. 15 Fundamentally, cytotoxic 
effect of mizoribine is caused by inhibition of syn- 
thesis of guanosine 5'-monophosphate in purine 
synthesis. 16 In organ toxicity, mizoribine causes no 
Scor¢ 
3 
Group I Group II Group Ili Group IV Group V Group VI 
Control No Tx. lw 2w 3w 3w 
I I 
Azathioprin¢ Mizoribine 
Fig. 5. Average epithelial regeneration score. Data are 
presented as mean +_ standard error. No Tx. indicates no 
treatment. The average score of group I differed signifi- 
cantly from the score of the other four groups (groups I 
versus II, p = 0.0018; I versus III, p = 0.0011; I versus IV, 
p = 0.0007; and I versus V,p = 0.0021), but did not differ 
significantly from the score of group VI (p = 0.3696). The 
average score of group VI differed significantly from the 
score of groups II, III, and IV. 
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3 
Group I1 Group III Group IV Group V Group VI 
No Tx. 1 w 2w 3w 3w 
I I 
Azathioprine Mizoribine 
Fig. 6. Average mononuclear cell infiltration score. Data 
are presented as mean -+ standard error. No Tx. indicates 
no treatment. In all comparisons of average score among 
groups II to VI, there was no difference. 
tracheal allografts may induce only weak rejection in 
the late phase after transplantation. Mizoribine may 
be an adequate immunosuppressant for allograft 
rejection of the trachea in the acute phase after 
transplantation. 
We conclude that an appropriate immunosup- 
pressive agent used for only a short period after 
transplantation may nearly maintain the viability of 
the tracheal allograft over a long period. It is 
important to aggressively prevent and treat allograft 
rejection in the early phase after transplantation. 
Additional study is required to determine the most 
appropriate late-phase immunosuppressive th rapy 
for tracheal allografts, such as whether low-dose 
consecutive or common-dose intermittent immuno- 
suppression is more beneficial. 
We thank Professor Masato Ikeda for performing the 
statistical evaluation and Ms. Miki Kiyofuji for her expert 
technical assistance. 
manifest liver dysfunction or bone marrow suppres- 
sion, as is often the case with azathioprine. 14 In 
pharmacokinetics, mizoribine is not significantly 
metabolized and depends on renal excretion for 
termination of its action. 13 Thus mizoribine has 
lesser side-effects but potency comparable with that 
of azathioprine. However, the dose of mizoribine 
equivalent o azathioprine still is not clear. We 
administered the two drugs at the same dosage of 5 
mg/kg per day. In experimental renal allotransplan- 
tation, azathioprine at a dosage of 5 mg/day did not 
prolong allograft survival when compared with the 
same dose of mizoribine because of pneumonia 
caused by side-effects such as leukopenia. 13In our 
study, graft patency, epithelial regeneration, and 
mononuclear cell infiltration of the graft did not 
differ significantly between groups V (azathioprine) 
and VI (mizoribine) at the same dosage, but sur- 
vival, alone, significantly differed. In other words, 
the immunosuppressive effect of these two drugs is 
almost equivalent, but untoward side-effects of aza- 
thioprine may decrease survival. Therefore, the dose 
of azathioprine may be inadequate for full immuno- 
suppression. Alternatively, mizoribine used for only 
3 weeks after transplantation maintained the mor- 
phologic features of the tracheal allografts over a 
long period, as evidenced by graft pateney and 
epithelial regeneration score. Mizoribine may better 
control allograft rejection in the acute phase after 
transplantation and then induce the allografts to 
almost attain immune tolerance. Alternatively, the 
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